Quris-AI Acquires Nortis (Numa Biosciences) Assets
October 29, 2024
Quris-AI has acquired the assets of Nortis (formerly Numa Biosciences) to integrate Nortis's Kidney-on-Chip microphysiology systems into Quris-AI's Bio-AI clinical prediction platform. The acquisition will combine Nortis's validated in-vitro kidney models with Quris-AI's machine-learning models and expand access to publicly funded MPS data while continuing collaborations with research institutes, the FDA and pharmaceutical partners.
- Buyers
- Quris-AI
- Targets
- Nortis (formerly Numa Biosciences, Inc.)
- Industry
- Biotechnology
- Location
- Washington, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Curi Bio Acquires South Korea-based Quvit Bio
January 12, 2026
Biotechnology
Curi Bio completed a full acquisition of South Korea-based Quvit Bio and has established Curi Bio Co., Ltd. as its Asia-Pacific commercial and operational hub. The deal integrates Quvit's imaging hardware, software and team to expand Curi Bio's localized sales, R&D and operational capabilities across South Korea, Japan and China.
-
Ciena Acquires Nubis Communications for $270 Million
September 25, 2025
IT Services
Ciena has announced a definitive agreement to acquire Nubis Communications in an all-cash deal valued at $270 million. The acquisition is intended to expand Ciena’s data center connectivity portfolio with Nubis’ high-performance optical and electrical interconnect technologies for AI workloads.
-
Qlik Acquires Intellectual Property and Technology from Kyndi
January 18, 2024
AI & Machine Learning
Qlik has acquired key intellectual property (patents and technology) from Kyndi, a developer of natural language processing, search, and generative AI, and will integrate Kyndi's unstructured-data capabilities into Qlik Cloud. Kyndi's CEO and several AI experts will join Qlik as part of the transaction, strengthening Qlik's ability to deliver context-rich, generative-AI answers that combine structured and unstructured data.
-
Optibrium Acquires BioPharmics LLC
August 31, 2023
Software
Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.
-
Somatus Acquires Strategic Assets from Lumiata
April 28, 2022
Healthcare Services
Somatus has acquired strategic assets from Lumiata to integrate Lumiata's healthcare AI and predictive analytics into Somatus' RenalIQ platform, improving early identification of people with chronic kidney disease and prediction of disease progression. The deal brings Lumiata talent (including Jessica McCarthy) into Somatus and aims to strengthen care delivery, reduce costs for provider and health-plan partners, and address health inequities.
-
Catabasis Pharmaceuticals Acquires Quellis Biosciences Inc.
January 29, 2021
Biotechnology
Catabasis Pharmaceuticals has acquired Quellis Biosciences in a stock-for-stock merger to obtain Quellis' lead preclinical monoclonal antibody program QLS-215 for hereditary angioedema. Concurrent with the acquisition, Catabasis completed a private placement (PIPE) led by Perceptive Advisors and other institutional investors to raise approximately $110 million to fund IND-enabling studies and early clinical trials of QLS-215.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.